İrem Bilgetekin

432 total citations
35 papers, 190 citations indexed

About

İrem Bilgetekin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, İrem Bilgetekin has authored 35 papers receiving a total of 190 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 8 papers in Surgery. Recurrent topics in İrem Bilgetekin's work include Renal cell carcinoma treatment (7 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). İrem Bilgetekin is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). İrem Bilgetekin collaborates with scholars based in Türkiye, Portugal and India. İrem Bilgetekin's co-authors include Berna Öksüzoğlu, Cengiz Karaçin, Ahmet Özet, Bülent Çetin, Umut Demırcı, İpek Işık Gönül, Aytuğ Üner, Özge Gümüşay, Aydın Çiltaş and Mehmet Alı Nahıt Şendur and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

İrem Bilgetekin

30 papers receiving 186 citations

Peers

İrem Bilgetekin

ONCOL

PRM

SURGE

Cengiz Karaçin Türkiye

Vittorio Gebbia Italy

Nicolas Delanoy France

Amir Montazeri United Kingdom

Asma Dilawari United States

Mireia Gil-Raga Spain

Michael Richardson United States

Blair McNamara United States

Kristen Zeligs United States

Deirdre Fitzpatrick United Kingdom

Cengiz Karaçin Türkiye

İrem Bilgetekin

173 ×1.7

ONCOL

68 ×1.1

PRM

51 ×1.3

21 ×0.7

46 ×2.1

SURGE

Citations per year, relative to İrem Bilgetekin İrem Bilgetekin (= 1×) peers Cengiz Karaçin

Countries citing papers authored by İrem Bilgetekin

Since Specialization

Citations

This map shows the geographic impact of İrem Bilgetekin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by İrem Bilgetekin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites İrem Bilgetekin more than expected).

Fields of papers citing papers by İrem Bilgetekin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by İrem Bilgetekin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by İrem Bilgetekin. The network helps show where İrem Bilgetekin may publish in the future.

Co-authorship network of co-authors of İrem Bilgetekin

This figure shows the co-authorship network connecting the top 25 collaborators of İrem Bilgetekin. A scholar is included among the top collaborators of İrem Bilgetekin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with İrem Bilgetekin. İrem Bilgetekin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bilgetekin, İrem, et al.. (2025). “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?. Medicina. 61(6). 1100–1100.

Karaçin, Cengiz, et al.. (2022). Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer. Journal of College of Physicians And Surgeons Pakistan. 32(11). 1501–1502.

Güven, Deniz Can, Ramazan Acar, Emre Yekedüz, et al.. (2021). The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. Current Problems in Cancer. 45(6). 100760–100760. 16 indexed citations

Bilir, Cemil, İlhan Hacıbekiroğlu, İbrahim Vedat Bayoğlu, et al.. (2021). Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Scientific Reports. 11(1). 14131–14131. 6 indexed citations

Doğan, Mutlu, Mehmet Artaç, Levent Korkmaz, et al.. (2021). The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. Journal of Gastrointestinal Cancer. 53(2). 356–362. 3 indexed citations

Karaçin, Cengiz, et al.. (2021). Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?. Urologia Internationalis. 105(7-8). 666–673. 9 indexed citations

Tural, Deniz, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.. (2021). Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.. Journal of Clinical Oncology. 39(6_suppl). 409–409. 1 indexed citations

Karaçin, Cengiz, et al.. (2020). Prognostic Importance of Metastatic Site in Intermediate-risk Group Metastatic Renal Cell Cancer Treated with Tyrosine Kinase Inhibitors. Journal of College of Physicians And Surgeons Pakistan. 30(6). 590–594. 3 indexed citations

Bilgetekin, İrem, et al.. (2020). Systemic Immune-inflammation Index is the Best Prognostic Factor in Patients with Advanced Stage Adenocarcinoma of the Lung Treated with Pemetrexed. Journal of College of Physicians And Surgeons Pakistan. 31(9). 933–939. 4 indexed citations

10.

Bilgetekin, İrem, et al.. (2020). Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel. Journal of College of Physicians And Surgeons Pakistan. 30(8). 815–821. 1 indexed citations

11.

Önür, Seda Tural, Deniz Yamaç, Cengiz Karaçin, et al.. (2020). Does a Secure Attachment Style Predict High Psychological Resilience in Patients With Cancer Receiving Chemotherapy?. Cureus. 12(10). e10954–e10954. 7 indexed citations

12.

Karaçin, Cengiz, et al.. (2020). Response to Trastuzumab Treatment and Number of Cycles ın Her2-Positive Metastatic Gastric Cancer Survival. Journal of College of Physicians And Surgeons Pakistan. 30(12). 1279–1284. 2 indexed citations

13.

Esin, Ece, et al.. (2019). Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies. SHILAP Revista de lepidopterología. 5(3). 96–99. 1 indexed citations

14.

Çetin, Bülent, Özge Gümüşay, Barış Afşar, et al.. (2019). Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib. Journal of Cancer Research and Therapeutics. 17(2). 408–413. 1 indexed citations

15.

Dizbay, Murat, et al.. (2019). Cost-Effectiveness Analysis of Low-Cost, Domestic Short Peripheral Catheters Versus Higher-Priced, Imported Short Peripheral Catheters. Journal of Infusion Nursing. 42(4). 209–214. 1 indexed citations

16.

Çetin, Bülent, İrem Bilgetekin, & Ahmet Özet. (2018). Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?. Current Problems in Cancer. 43(1). 43–53. 1 indexed citations

17.

Çetin, Bülent, İrem Bilgetekin, Mustafa Cengiz, & Ahmet Özet. (2018). Managing Synchronous Liver Metastases in Colorectal Cancer. Indian Journal of Surgical Oncology. 9(4). 461–471. 5 indexed citations

18.

Aytekin, Aydın, et al.. (2018). A metastatic histiocytic sarcoma case with primary involvement of the tonsil. Journal of Cancer Research and Therapeutics. 16(3). 665–667. 1 indexed citations

19.

Çetin, Bülent, Güldal Yılmaz, Berkan Armağan, et al.. (2018). Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model. Chemotherapy. 63(1). 39–45. 4 indexed citations

20.

Bilgetekin, İrem, Bülent Çetin, & Ahmet Özet. (2017). Antiangiogenic therapy in ovarian cancer – for whom and when?. Zenodo (CERN European Organization for Nuclear Research). 15(1). 78–85. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact